CN113164415A - 依拉司群和阿贝西利在患乳腺癌女性中的联合应用 - Google Patents

依拉司群和阿贝西利在患乳腺癌女性中的联合应用 Download PDF

Info

Publication number
CN113164415A
CN113164415A CN201980079089.6A CN201980079089A CN113164415A CN 113164415 A CN113164415 A CN 113164415A CN 201980079089 A CN201980079089 A CN 201980079089A CN 113164415 A CN113164415 A CN 113164415A
Authority
CN
China
Prior art keywords
patient
dose
administered
day
abeccil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079089.6A
Other languages
English (en)
Chinese (zh)
Inventor
N·K·阿拉甘
C·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of CN113164415A publication Critical patent/CN113164415A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980079089.6A 2018-11-30 2019-11-26 依拉司群和阿贝西利在患乳腺癌女性中的联合应用 Pending CN113164415A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
US62/773,960 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (1)

Publication Number Publication Date
CN113164415A true CN113164415A (zh) 2021-07-23

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079089.6A Pending CN113164415A (zh) 2018-11-30 2019-11-26 依拉司群和阿贝西利在患乳腺癌女性中的联合应用

Country Status (18)

Country Link
US (3) US20220117963A1 (https=)
EP (1) EP3886826A1 (https=)
JP (2) JP2022509262A (https=)
KR (1) KR20210097170A (https=)
CN (1) CN113164415A (https=)
AU (1) AU2019388900B2 (https=)
BR (1) BR112021010169A2 (https=)
CA (1) CA3120368A1 (https=)
EA (1) EA202191165A1 (https=)
IL (1) IL283502A (https=)
JO (1) JOP20210125A1 (https=)
MA (1) MA54293A (https=)
MX (1) MX2021005876A (https=)
MY (1) MY209833A (https=)
PH (1) PH12021551235A1 (https=)
SG (1) SG11202105455RA (https=)
UA (1) UA129403C2 (https=)
WO (1) WO2020112765A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
CN108024540A (zh) * 2015-04-29 2018-05-11 雷迪厄斯制药公司 用于治疗癌症的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024540A (zh) * 2015-04-29 2018-05-11 雷迪厄斯制药公司 用于治疗癌症的方法
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUNIL PANCHOLI等: "Impact of oral selective estrogen receptor degrader RAD1901 in preclinical models of endocrine sensitive/resistant breast cancer", CANCER RES, vol. 77, pages 4160 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Also Published As

Publication number Publication date
JOP20210125A1 (ar) 2019-11-26
EP3886826A1 (en) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MA54293A (fr) 2021-10-06
BR112021010169A2 (pt) 2021-08-17
MY209833A (en) 2025-08-07
JP2025094216A (ja) 2025-06-24
SG11202105455RA (en) 2021-06-29
KR20210097170A (ko) 2021-08-06
PH12021551235A1 (en) 2021-12-13
US20260014153A1 (en) 2026-01-15
EA202191165A1 (ru) 2021-09-21
AU2019388900B2 (en) 2025-09-04
CA3120368A1 (en) 2020-06-04
US20250268899A1 (en) 2025-08-28
AU2019388900A1 (en) 2021-06-10
JP2022509262A (ja) 2022-01-20
IL283502A (en) 2021-07-29
US20220117963A1 (en) 2022-04-21
MX2021005876A (es) 2021-07-16
UA129403C2 (uk) 2025-04-16

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
CN113164415A (zh) 依拉司群和阿贝西利在患乳腺癌女性中的联合应用
CN113164779A (zh) 治疗cdk4/6抑制剂耐药性癌症的方法
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
HK40064613A (en) Methods for treating cancer
CA2984357C (en) Methods for treating cancer
EA045102B1 (ru) Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination